Skip to content

Detection of mandibular gingival cancer, using fluciclovine PET/CT

Application of Fluciclovine PET/CT for the Detection of Mandibular Gingival Carcinoma Including Central Mandibular Carcinoma - OSCC-FACBC

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs031250393
Enrollment
5
Registered
2025-09-29
Start date
2025-09-29
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mandibular gingival carcinoma (including central mandibular carcinoma) Mandibular gingival carcinoma, Central mandibular carcinoma

Interventions

Administration of fluciclovine (^18F-FACBC) PET/CT to evaluate tracer uptake in mandibular gingival carcinoma (including central mandibular carcinoma). The uptake patterns will be compared with those
C000606581(Fluciclovine F 18)
Fluciclovine PET/CT PET/CT

Sponsors

Kim Mai
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion Criteria Patients who meet all of the following criteria will be eligible for this study: 1. Patients with mandibular gingival carcinoma (in cluding central mandibular carcinoma) who requir e surgical treatment based on the Clinical Practice Guidelines for Oral Cancer. 2. Patients aged 20 years or older and younger th an 75 years at the time of obtaining informed cons ent. 3. Patients with a performance status of 0-1. 4. Patients from whom written informed consent f or participation in this study can be obtained.

Exclusion criteria

Exclusion criteria: Exclusion Criteria Patients who meet any of the following criteria will be excluded from the study: 1. Patients who are pregnant, breastfeeding, or possibly pregnant. 2. Patients judged to be inappropriate for particip ation by the principal investigator or sub-investiga tors. 3. Patients whose scheduled surgery date is less t han 7 days after providing informed consent for this study. 4. Patients with hypersensitivity to the components of the investigational drug.

Design outcomes

Primary

MeasureTime frame
Fluciclovine PET uptake in mandibular gingival carcinoma (including central mandibular carcinoma)

Secondary

MeasureTime frame
If uptake in the tumour is confirmed, the following will be evaluated: - Comparison of tumour uptake extent with FDG PET images - Numerical comparison using semi-quantitative parameters (SUV parameters) - Comparison between the resected pathological specimen volume and uptake on fluciclovine PET/CT or FDG PET/CT

Countries

Japan, Not applicable

Contacts

Public ContactMai Kim

Gunma University Hospital

kimmu@gunma-u.ac.jp+81-272208484

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026